Moderna's covid vaccine enters final trial: 10 updates1 min read . Updated: 27 Jul 2020, 05:31 PM IST
- The US government has doubled funding support for Moderna's coronavirus vaccine
- Moderna had reported promising results from early stage trials
US-based Moderna today started the final phase of trial of its coronavirus vaccine today, involving about 30,000 participants. Moderna joined Oxford University-AstraZenica and two other Chinese companies whose covid vaccines are already undergoing the phase 3 trial. The US has has suffered more than 1.46 lakh coronavirus-related deaths, the highest in the world even as the number of new cases has continued to surge.
Here are key updates of Moderna coronavirus vaccine trial:
1) Moderna's coronavirus vaccine uses synthetic messenger RNA (mRNA) to inoculate against the coronavirus.
2) Such treatments help the body immunize against a virus and can potentially be developed and manufactured more quickly than traditional vaccines.
3) The trial, named COVE, is the first to be implemented under the U.S. government's Operation Warp Speed that aims to accelerate the development, manufacturing and distribution of therapeutics and vaccines for COVID-19.
4) The main goal of the study will be prevention of the symptomatic COVID-19 disease, the company said.
5) Ahead of the phase 3 trial, Moderna received an additional $472 million from the U.S. government to support development of its novel coronavirus vaccine.
6) This takes the total funding from US government for Moderna's vaccine program to about $1 billion. In April, Moderna had received $483 million from the U.S. federal agency that funds disease-fighting technology.
7) In the expanded trial starting today, half the 30,000 participants will receive a 100-microgram dose of the vaccine, while the rest will be given a placebo.
8) Moderna said it remains on track to be able to deliver about 500 million doses per year, and possibly up to 1 billion doses per year, beginning in 2021.
9) In a small, initial trial, Moderna's experimental covid vaccine reported promising results by producing coronavirus antibodies in the bodies of all 45 participants.
10) Earlier this week, the American-German BioNTech/Pfizer pharmaceutical alliance announced that the US government had committed $1.95 billion to procure 100 million doses of its eventual vaccine. (With Agency Inputs)